Related Experiment Video

Updated: Jan 17, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

349

Research progress and challenges in the treatment of oncogene-addicted non-small cell lung cancer

Hanyi Li1,2, Xuanguang Li1,2, Tong Li1,2

  • 1Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin 300052, China.

Cancer Biology & Medicine
|September 24, 2025
PubMed

Insights

Recent advancements in non-small cell lung cancer (NSCLC) treatment, including targeted therapies and immunotherapies, have significantly improved patient outcomes. This review highlights key findings in NSCLC targeted therapy from major 2024 oncology conferences.

Area of Science:

  • Oncology
  • Medical Genetics
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) treatment has seen major progress over 20 years.
  • Targeted therapies and novel treatments have improved patient outcomes.

Purpose of the Study:

  • To review current advancements in NSCLC targeted therapy.
  • To synthesize findings from major 2024 oncology conferences and PubMed.

Main Methods:

  • Systematic search of the PubMed database.
  • Synthesis of data from the 2024 American Society of Clinical Oncology Annual Meeting and 2024 World Conference on Lung Cancer.

Main Results:

  • Tyrosine kinase inhibitors targeting EGFR, ALK, RET, BRAF, ROS1, NTRK, MET, and KRAS show significant antitumor activity.
  • Immunotherapy and antibody-drug conjugate therapies offer benefits for NSCLC patients.
  • Recent conference data highlights cutting-edge developments in NSCLC treatment.

Conclusions:

  • Targeted therapies are integral to modern NSCLC treatment regimens.
  • Novel therapies like immunotherapy continue to advance NSCLC care.
  • Ongoing research and conference findings drive progress in NSCLC management.
Keywords:
Non-small cell lung canceracquired resistanceactionable gene mutationconsolidation therapytyrosine kinase inhibitors

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K